Schizophrenia / Psychosis – Society of Cannabis Clinicians https://www.cannabisclinicians.org Educating Healthcare Professionals about the Medical Use of Cannabis Thu, 21 Sep 2023 00:01:14 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.3 https://www.cannabisclinicians.org/wp-content/uploads/2020/07/cropped-scc-flavicon-32x32.png Schizophrenia / Psychosis – Society of Cannabis Clinicians https://www.cannabisclinicians.org 32 32 Increased Hippocampal Blood Flow in People at Clinical High Risk for Psychosis and Effects of Cannabidiol https://www.cannabisclinicians.org/2023/09/20/increased-hippocampal-blood-flow-in-people-at-clinical-high-risk-for-psychosis-and-effects-of-cannabidiol/ Thu, 21 Sep 2023 00:01:14 +0000 https://www.cannabisclinicians.org/?p=29232 Hippocampal hyperperfusion has been observed in people at Clinical High Risk for Psychosis (CHR), is associated with adverse longitudinal outcomes and represents a potential treatment target for novel pharmacotherapies. Whether cannabidiol (CBD) has ameliorative effects on hippocampal blood flow (rCBF) in CHR patients remains unknown. Using a double-blind, parallel-group design, 33 CHR patients were randomised to a single oral 600mg dose of CBD or placebo; 19 healthy controls did not receive any drug. Hippocampal rCBF was measured using Arterial Spin Labelling. We examined differences relating to CHR status (controls vs placebo), effects of CBD in CHR (placebo vs CBD) and linear between-group relationships, such that placebo>CBD>controls or controls>CBD>placebo, using a combination of hypothesis-driven and exploratory wholebrain analyses.

The post Increased Hippocampal Blood Flow in People at Clinical High Risk for Psychosis and Effects of Cannabidiol appeared first on Society of Cannabis Clinicians.

]]> Recreational cannabis use over time in individuals at clinical high risk for psychosis: Lack of associations with symptom, neurocognitive, functioning, and treatment patterns https://www.cannabisclinicians.org/2023/09/06/recreational-cannabis-use-over-time-in-individuals-at-clinical-high-risk-for-psychosis-lack-of-associations-with-symptom-neurocognitive-functioning-and-treatment-patterns/ Wed, 06 Sep 2023 11:54:07 +0000 https://www.cannabisclinicians.org/?p=29156 Recreational cannabis use has recently gained considerable interest as an environmental risk factor that triggers the onset of psychosis. To date, however, the evidence that cannabis is associated with negative outcomes in individuals at clinical high risk (CHR) for psychosis is inconsistent. The present study tracked cannabis usage over a 2-year period and examined its associations with clinical and neurocognitive outcomes, along with medication rates. CHR youth who continuously used cannabis had higher neurocognition and social functioning over time, and decreased medication usage, relative to non-users. Surprisingly, clinical symptoms improved over time despite the medication decreases.

The post Recreational cannabis use over time in individuals at clinical high risk for psychosis: Lack of associations with symptom, neurocognitive, functioning, and treatment patterns appeared first on Society of Cannabis Clinicians.

]]> The Impact Of Cannabidiol In Patients With Early Psychosis: A Randomized Controlled Trial https://www.cannabisclinicians.org/2023/07/09/the-impact-of-cannabidiol-in-patients-with-early-psychosis-a-randomized-controlled-trial/ Sun, 09 Jul 2023 19:46:35 +0000 https://www.cannabisclinicians.org/?p=28897 We aimed to study the effects of cannabidiol (CBD) in out-patients with early psychosis on clinical metrics of psychosis and cognition and on psychophysiological electroencephalogram (EEG) metrics of psychosis. Adult outpatient subjects with a primary psychotic disorder within approximately five years of psychosis onset were enrolled in a four-week, two-period, randomized, placebo-controlled crossover trial (clinicaltrials.gov NCT02504151). Subjects were randomized in a one-to-one ratio to receive either CBD (oral 800 mg/day) or placebo in the first of two treatment periods in a randomized, double-blind manner. Primary outcome measures assessed were psychosis symptoms measured using the Positive and Negative Syndrome Scale (PANSS); and cognition measured using the MATRICS Consensus Cognitive Battery (MCCB). Secondary clinical outcomes included Clinical Global Impression of Severity or of Improvement (CGI-S, CGI-I) and Quality of Life Scale (QLS). Statistical analyses were conducted using linear mixed models and nonparametric tests.

The post The Impact Of Cannabidiol In Patients With Early Psychosis: A Randomized Controlled Trial appeared first on Society of Cannabis Clinicians.

]]> Association between cannabis use disorder and schizophrenia stronger in young males than in females https://www.cannabisclinicians.org/2023/05/21/association-between-cannabis-use-disorder-and-schizophrenia-stronger-in-young-males-than-in-females/ Mon, 22 May 2023 01:02:18 +0000 https://www.cannabisclinicians.org/?p=28660 Previous research suggests an increase in schizophrenia population attributable risk fraction (PARF) for cannabis use disorder (CUD). However, sex and age variations in CUD and schizophrenia suggest the importance of examining differences in PARFs in sex and age subgroups. We conducted a nationwide Danish register-based cohort study including all individuals aged 16–49 at some point during 1972–2021. CUD and schizophrenia status was obtained from the registers. Hazard ratios (HR), incidence risk ratios (IRR), and PARFs were estimated. Joinpoint analyses were applied to sex-specific PARFs.

The post Association between cannabis use disorder and schizophrenia stronger in young males than in females appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol goes nuclear: The role of PPARγ https://www.cannabisclinicians.org/2023/03/17/cannabidiol-goes-nuclear-the-role-of-ppar%ce%b3/ Fri, 17 Mar 2023 22:41:53 +0000 https://www.cannabisclinicians.org/?p=28080 Cannabidiol (CBD) is one of the main phytocannabinoids found in Cannabis sativa. In contrast to Δ9-tetrahydrocannabinol, it has a low affinity for cannabinoid receptors CB1 and CB2, thereby it does not induce significant psychoactive effects. However, CBD may interact with other receptors, including peroxisome proliferator-activated receptor gamma (PPARγ). CBD is a PPARγ agonist and changes its expression. There is considerable evidence that CBD's effects are mediated by its interaction with PPARγ. So, we reviewed studies related to the interaction of CBD and PPARγ.

The post Cannabidiol goes nuclear: The role of PPARγ appeared first on Society of Cannabis Clinicians.

]]> Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis https://www.cannabisclinicians.org/2023/01/23/cannabis-use-is-associated-with-low-plasma-endocannabinoid-anandamide-in-individuals-with-psychosis/ Mon, 23 Jan 2023 12:57:57 +0000 https://www.cannabisclinicians.org/?p=27578 Cannabis use suppresses the endocannabinoid system in healthy individuals. However, the association between cannabis use with the endocannabinoid system is understudied in individuals with psychosis despite the high rate of cannabis use in these individuals.

The post Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis appeared first on Society of Cannabis Clinicians.

]]> The therapeutic role of Cannabidiol in mental health: a systematic review https://www.cannabisclinicians.org/2022/03/14/the-therapeutic-role-of-cannabidiol-in-mental-health-a-systematic-review/ Mon, 14 Mar 2022 22:50:22 +0000 https://www.cannabisclinicians.org/?p=26278 The therapeutic application of cannabidiol (CBD) is gaining interest due to expanding evidence for its use.
Objective: To summarize the clinical outcomes, study designs and limitations for the use of CBD and nabiximols (whole plant extract from Cannabis sativa L. that has been purified into 1:1 ratio of CBD and delta-9- tetrahydrocannabinol) in the treatment of psychiatric disorders.

The post The therapeutic role of Cannabidiol in mental health: a systematic review appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study https://www.cannabisclinicians.org/2021/12/08/cannabidiol-cigarettes-as-adjunctive-treatment-for-psychotic-disorders-a-randomized-open-label-pilot-study/ Thu, 09 Dec 2021 02:10:40 +0000 https://www.cannabisclinicians.org/?p=25437 The main aim of the study was to clarify the antipsychotic potential of CBD used as adjunctive therapy simulating a naturalistic setting. Our trial is the first study evaluating the effects of smoked CBD-cigarettes as adjunctive therapy for psychotic symptoms.

The post Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study appeared first on Society of Cannabis Clinicians.

]]> FURTHER EVIDENCE OF ANXIETY- AND DEPRESSION-LIKE BEHAVIOR FOR TOTAL GENETIC ABLATION OF CANNABINOID RECEPTOR TYPE 1 https://www.cannabisclinicians.org/2020/11/16/further-evidence-of-anxiety-and-depression-like-behavior-for-total-genetic-ablation-of-cannabinoid-receptor-type-1/ Mon, 16 Nov 2020 16:05:00 +0000 https://www.cannabisclinicians.org/?p=20587 Authors: Delia Soriano, Alicia Brusco, Laura Caltana Published in Behavioural Brain Research November 2020 Abstract Cannabinoid receptor type 1 (CB1R) is the most abundant cannabinoid receptor in central nervous system....

The post FURTHER EVIDENCE OF ANXIETY- AND DEPRESSION-LIKE BEHAVIOR FOR TOTAL GENETIC ABLATION OF CANNABINOID RECEPTOR TYPE 1 appeared first on Society of Cannabis Clinicians.

]]> A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis https://www.cannabisclinicians.org/2020/10/12/a-single-dose-of-cannabidiol-modulates-medial-temporal-and-striatal-function-during-fear-processing-in-people-at-clinical-high-risk-for-psychosis/ Mon, 12 Oct 2020 20:59:30 +0000 https://www.cannabisclinicians.org/?p=20043 Authors: Cathy Davies, Robin Wilson, Elizabeth Appiah-Kusi, Grace Blest-Hopley, Michael Brammer, Jesus Perez, Robin M Murray, Paul Allen, Matthijs G Bossong, Philip McGuire, Sagnik Bhattacharyya Published in Translational Psychiatry September...

The post A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis appeared first on Society of Cannabis Clinicians.

]]>